Author: NSV

Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap CDP, the easy, secure and impactful Customer Data Platform (CDP) has established a strategic partnership with Artefact, a global data consulting service specialist. This collaboration will help to deliver effective data-driven marketing while prioritising consumer privacy and security. Enterprises will benefit from a holistic and integrated approach that will

Read More
Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system

Read More
Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the

Read More
Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections

Read More
Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become

Read More
Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of

Read More
Isorg collaborates with Precise Biometrics on turnkey fingerprint sensor solution for smartphone industry

Isorg collaborates with Precise Biometrics on turnkey fingerprint sensor solution for smartphone industry

Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, announces further details on the company’s collaboration with Precise Biometrics, a leader in fingerprint verification software, on a new Fingerprint on Display (FoD) solution for the mobile industry. While increasing resolution unquestionably remains a major trend within the

Read More
Isorg’s FAP30 optical fingerprint sensor obtains FBI certification

Isorg’s FAP30 optical fingerprint sensor obtains FBI certification

Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, has announced the FBI certification of Bio1Print30, a large-area optical fingerprint sensor for applications where enhanced mobile security and nomad ID authentication are key. The Bio1Print30, a FAP30 (Fingerprint Acquisition Profile) device, whose core technology is compatible with

Read More
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment

Read More
Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma

Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its

Read More
Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis

Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for

Read More
Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial

Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, has announced that its Phase II clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121). The randomized, double-blind, placebo- controlled study in patients with long covid who are suffering from debilitating fatigue has enrolled

Read More